Arthur He
Stock Analyst at HC Wainwright & Co.
(4.44)
# 328
Out of 5,090 analysts
45
Total ratings
54.17%
Success rate
22.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VERA Vera Therapeutics | Maintains: Buy | $85 → $90 | $44.90 | +100.45% | 3 | Nov 10, 2025 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.99 | +251.76% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $15.62 | +8.83% | 1 | Jul 30, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $56.90 | +110.90% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.77 | +246.62% | 10 | Jun 17, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.74 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.82 | - | 8 | Mar 31, 2025 |
Vera Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $85 → $90
Current: $44.90
Upside: +100.45%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.99
Upside: +251.76%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $15.62
Upside: +8.83%
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $56.90
Upside: +110.90%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.77
Upside: +246.62%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.74
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.82
Upside: -